Globally recognized thought leader in cell and gene therapy; Senior executive with >25 years of experience in evidence generation, value, and access for innovative life sciences products. Cross-organizational experience leading integrated value and access approaches that pull from multiple business disciplines. Broad therapeutic area expertise, including rare disease, oncology, and other chronic disease areas, including >350 precision medicine and >250 cell and gene therapy scenarios with limited or no global market precedent. Expert advisor, steering committee and advisory group member, managed care institute leader, and adjunct Assistant Professor. Expertise includes:
Strategy & Execution | Market Access | HEOR | Real-world Evidence | Integrated Development & Launch | Disruptive Product Reimbursement | Commercialization | Pipeline Optimization | Business Function Strategy & Management | Health System Change
Strategy & Execution | Market Access | HEOR | Real-world Evidence | Integrated Development & Launch | Disruptive Product Reimbursement | Commercialization | Pipeline Optimization | Business Function Strategy & Management | Health System Change